# 2026-12906: FDA Ends Emergency Use for Three Old COVID Tests

2026-12906, Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-02-24; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12906
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12906
- Title: Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38720
- Published: 2026-06-26
- Effective: 2026-02-24
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## In one line

FDA Ends Emergency Use for Three Old COVID Tests

## Summary

The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.

## Abstract

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Becton, Dickinson and Company (BD) for the BD Veritor System for Rapid Detection of SARS-CoV-2, InBios International, Inc. for the SCoV-2 Detect Neutralizing Ab ELISA, and Roche Diagnostics for the Elecsys Anti-SARS-CoV-2. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.

## Effects PRIA read

- BD Veritor EUA Revoked Feb 24, 2026: cost, low. FDA revoked the Emergency Use Authorization (EUA) for the BD Veritor System for Rapid Detection of SARS-CoV-2 effective February 24, 2026. BD requested the revocation, told FDA there are no viable BD Veritor reagents remaining in U.S. distribution, and has transitioned to a cleared BD Veritor produ…
- InBios SCoV-2 Detect EUA Revoked Feb 24, 2026: cost, low. FDA revoked the Emergency Use Authorization (EUA) for InBios International, Inc.'s SCoV-2 Detect Neutralizing Ab ELISA effective February 24, 2026. InBios requested the revocation and stated there are no viable SCoV-2 Detect Neutralizing Ab ELISA reagents remaining in U.S. distribution; the revoked…
- Roche Elecsys EUA Revoked March 2, 2026: cost, low. FDA revoked the Emergency Use Authorization (EUA) for Roche Diagnostics' Elecsys Anti-SARS-CoV-2 effective March 2, 2026. Roche requested the revocation, indicated there are no viable Elecsys reagents remaining in U.S. distribution, and has transitioned to a cleared Elecsys product under K250768; t…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12906 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12906/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection)
- [2026-12906 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12906.pdf)

## Related
- [Previous: 2026-12893, Combined Notice of Filings #1](https://policyrisk.com/federal-register/2026-12893)
- [Next: 2026-12907, Evaluation of the California Coastal Management Program; Notice of Public Meeti…](https://policyrisk.com/federal-register/2026-12907)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12906 (as of 2026-07-03).
